Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Gemcitabine vs Gemcitabine in Elderly NSCLC
NCT00442026Phase 3Terminated
- Sponsor
- Hellenic Oncology Research Group
- Start
- Dec 2006
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Hellenic Oncology Research Group. Primary endpoint: Overall Survival at 1 year. Started Dec 2006; status: terminated.
02
Drugs
docetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00442026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00442026.